Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 54 (Search time: 0.002 seconds).
previous
1
2
3
4
...
6
next
Item hits:
Preview
Issue Date
Title
Author(s)
2002
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
Frost, M.
;
Ferrao, P.
;
Hughes, T.
;
Ashman, L.
2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Grigg, A.
;
Arthur, C.
;
Taylor, K.
;
Herrmann, R.
;
Lynch, K.
;
Hughes, T.
2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, B.
;
Guilhot, F.
;
O'Brien, S.
;
Gathmann, I.
;
Kantarjian, H.
;
Gattermann, N.
;
Deininger, M.
;
Silver, R.
;
Goldman, J.
;
Stone, R.
;
Cervantes, F.
;
Hochhaus, A.
;
Powell, B.
;
Gabrilove, J.
;
Rousselot, P.
;
Reiffers, J.
;
Cornelissen, J.
;
Hughes, T.
;
Agis, H.
;
Fischer, T.
;
et al.
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Branford, S.
;
Yeung, D.
;
Parker, W.
;
Roberts, N.
;
Purins, L.
;
Braley, J.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Donaldson, Z.
;
Leong, M.
;
Fletcher, L.
;
Seymour, J.
;
Grigg, A.
;
Ross, D.
;
Hughes, T.
2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Hughes, T.
;
Lipton, J.
;
Spector, N.
;
Cervantes, F.
;
Pasquini, R.
;
Clementino, N.
;
Dorlhiac Llacer, P.
;
Schwarer, A.
;
Mahon, F.
;
Rea, D.
;
Branford, S.
;
Purkayastha, D.
;
Collins, L.
;
Szczudlo, T.
;
Leber, B.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Olshen, A.
;
Tang, M.
;
Cortes, J.
;
Gonen, M.
;
Hughes, T.
;
Branford, S.
;
Quintás-Cardama, A.
;
Michor, F.
2014
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
Eadie, L.
;
Hughes, T.
;
White, D.
2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Prime, J.
;
Field, C.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Sullivan, B.
;
Briggs, N.
;
Hertzberg, M.
;
Seymour, J.
;
Reynolds, J.
;
Hughes, T.
Discover
Author
20
Branford, S.
19
Hochhaus, A.
14
White, D.
13
Kantarjian, H.
12
Larson, R.
12
Saglio, G.
10
Radich, J.
9
Cortes, J.
9
Kim, D.
8
Guilhot, F.
.
next >
Subject
19
Female
19
Treatment Outcome
18
Adult
17
Middle Aged
16
Aged
13
Drug Resistance, Neoplasm
10
Protein-Tyrosine Kinases
10
Time Factors
8
Disease-Free Survival
8
Leukemia, Myeloid, Chronic-Phase
.
< previous
next >
Date issued
30
2010 - 2014
24
2002 - 2009